Pfizer's failed development of oral weight loss drugs has no hope of turning around in the short term
阿豆学长长ov
发表于 2023-12-2 10:18:54
311
0
0
The best performing companies in the healthcare sector this year have all benefited from the weight loss drug boom. Pfizer also hopes to make a comeback with an oral weight loss drug, but the latest developments have raised concerns on Wall Street. On Friday local time, Pfizer announced plans to abandon the development of its experimental weight loss drug danuglipron (taken orally twice a day). As of the time of publication, its stock price has fallen by over 6%, with a decline of nearly 40% for the year.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Exhibits become commodities in seconds! Prostate cancer new drug approved in China, Pfizer Wang Yu: promoting China's new drug market to synchronize with the global market
- Exploring the CIIE | New products from Sinogen, Roche, and Pfizer become highlights of the CIIE
- Pfizer plans to sell hospital drug division, company responds
- After closing factories and laying off employees, Pfizer is reportedly considering selling its hospital drug division
- Pfizer and CR Pharma reach strategic partnership on four mature drugs
- Top 20 US stock transactions: Eli Lilly rises over 4%, Biden administration plans to include weight loss drugs in healthcare and subsidy programs
- Pfizer expects revenue of $61 billion to $64 billion in 2025, with an estimated $63.23 billion
- After more than two years, there is finally no shortage of Zepbound, a weight loss medication from Eli Lilly
- Lilly weight loss pills are now available for purchase on e-commerce platforms. Lilly China responds that they are self funded drugs
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy